

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum

Dimitrios Boumpas

Gerd Burmester

Mary Crow

Iain McInnes

Thomas Pap

David Pisetsky

Desirée van der Heijde

Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 3655 5889

E: ard@bmj.com

Twitter: @ARD_BMJ

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Impact Factor: 12.350

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2019 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 153** Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?
J A Singh

Reviews

- 155** Management of antiphospholipid syndrome
I Uthman, M H A Noureldine, G Ruiz-Irastorza, M Khamashta
- 162** Clinical trials in children and adolescents with systemic lupus erythematosus : methodological aspects, regulatory landscape and future opportunities
H I Brunner, A Martini, D J Lovell, N Ruperto, On behalf of Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

Rheumatoid arthritis

- 171** Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
T Takeuchi, M C Genovese, B Haraoui, Z Li, L Xie, R Klar, A Pinto-Correia, S Otawa, P Lopez-Romero, I de la Torre, W Macias, T P Rooney, J S Smolen

- 179** Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
D M Gerlag, M Safy, K I Maijer, M W Tang, S W Tas, M J F Starmans-Kool, A van Tubergen, M Janssen, M de Hair, M Hansson, N de Vries, A H Zwinderman, P P Tak

Inflammatory arthritis

- 186** Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?
S R Aungier, A J Cartwright, A Schwenger, J L Marshall, M R Dyson, P Slavny, K Parthiban, A Karatt-Vellatt, I Sahbudin, E Culbert, P Hextall, F IL Clanchy, R Williams, B D Marsden, K Raza, A Filer, C D Buckley, J McCafferty, K S Midwood

- 192** To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
B Glimborg, A G Loft, E Omerovic, O Hendricks, A Linauskas, J Espesen, K Danebod, D V Jensen, H Nordin, E B Dalgaard, S Chrysidis, S Kristensen, J L Raun, H Lindegaard, N Manilo, S H Jakobsen, I M J Hansen, D Dalsgaard Pedersen, I J Sørensen, L S Andersen, J Grydehøj, F Mehnert, N S Krogh, M L Hetland

Psoriatic arthritis

- 201** Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries
C Gorlier, A-M Orbai, D Puyraimond-Zemmour, L C Coates, U Kiltz, Y-Y Leung, P Palominos, J D Cañete, R Scrivo, A Balanescu, E Dernis, S Tälli, A Ruysen-Witrand, M Soubrier, S Z Aydın, L Eder, I Gaydukova, E Lubrano, U Kalyoncu, P Richette, M E Husni, M de Wit, J S Smolen, L Gossec

Connective tissue diseases

- 209** Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
M Rosenzweig, R Lorenzon, P Cacoub, H P Pham, F Pitoiset, K El Soufi, C Ribet, C Bernard, S Aractingi, B Banneville, L Beaugerie, F Berenbaum, J Champey, O Chazouilleres, C Corpechot, B Fautrel, A Mekinian, E Regnier, D Saadoun, J-E Salem, J Sellam, P Seksik, A Dagenel-Nguyen, V Doppler, J Mariau, E Vicaut, D Klitzmann
- 218** Visualisation of interstitial lung disease by molecular imaging of integrin $\alpha\beta 3$ and somatostatin receptor 2
J Schniering, M Benešová, M Brunner, S Haller, S Cohrs, T Frauenfelder, B Vrugt, C A Feghali-Bostwick, R Schibli, O Distler, C Mueller, B Maurer
- 228** Humanised effector-null Fc γ RIIA antibody inhibits immune complex-mediated proinflammatory responses
B Chen, K A Vousden, B Naiman, S Turman, H Sun, S Wang, L M K Vinall, B P Kemp, S Kasturiangan, D G Rees, E Grant, M J Hinrichs, S Ecker, A DiGiandomenico, M Jack Borrok, N Ly, X Xiong, C Gonzalez, C Morehouse, Y Wang, Y Zhou, J Cann, W Zhao, H Koelkebeck, K Okubo, T N Mayadas, D Howe, J Griffiths, R Kolbeck, R Herbst, G P Sims

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008

JMD0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

Systemic lupus erythematosus

- 238** REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)



E Frangou, A Chrysanthopoulou, A Mitsios, K Kambas, S Arelaki, I Angelidou, A Arampatzioglou, H Gakiopoulou, G K Bertias, P Verginis, K Ritis, D T Boumpas

Sjögren's syndrome

- 249** Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome



S Nayar, J Campos, C G Smith, V Iannizzotto, D H Gardner, S Colafrancesco, E Papi, F Kollert, K J Hunter, C Brewer, C D Buckley, S J Bowman, R Priori, G Valesini, M Juarez, W A Fahy, B A Fisher, A Payne, R A Allen, F Barone

Vasculitis

- 261** Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data



A Tracy, A Subramanian, N J Adderley, P Cockwell, C Ferro, S Ball, L Harper, K Nirantharakumar

Osteoarthritis

- 270** RNA sequencing data integration reveals a miRNA interactome of osteoarthritis cartilage



R Coutinho de Almeida, Y F M Ramos, A Mahfouz, W den Hollander, N Lakenberg, E Houtman, M van Hoolwerff, H E D Suchiman, A Rodríguez Ruiz, P E Slagboom, H Mei, S M Kielhasa, R G H H Nelissen, M Reinders, I Meulenbelt

Letters

- 279** How to reduce the waiting time for the first consultation with the rheumatologist as a first step for a timely treatment

O Valenzuela, S E Ibáñez Vodnizza

- 279** Chronic hydroxychloroquine/chloroquine exposure for connective tissue diseases and risk of Alzheimer's disease: a population-based cohort study

L Fardet, I Nazareth, I Petersen

- 282** Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis

J K Park, Y J Lee, S Bitoun, K L Winthrop, Y Choi, E B Lee, X Mariette

- 284** Significant joint-destructive association of HLA-DRB1*04:05 independent of DAS28 in rheumatoid arthritis

H Tsuji, K Ikari, K Ohmura, K Yano, M Furu, M Hashimoto, H Ito, T Fujii, W Yamamoto, A Taniguchi, H Yamanaka, T Mimori, C Terao

- 286** Prevalence and incidence of psoriasis and psoriatic arthritis

P Sewerin, R Brinks, M Schneider, I Haase, S Vordenbäumen

- 287** Evaluation of retinal microvascular density in patients affected by systemic lupus erythematosus: an optical coherence tomography angiography study

P Conigliaro, M Cesareo, M S Chimenti, P Triggianese, C Canofari, G Aloe, C Nucci, R Perricone

- 289** Kawasaki disease in infants 3 months of age and younger: a multicentre Spanish study

C D Grasa, E Fernandez-Cooke, J Sánchez-Manubens, J Antón, D Crespo, M García, A López, M J Lirio Cruz, R Díaz-Delgado de la Peña, C Calvo, On behalf of the Spanish network for the study of Kawasaki disease, KAWA-RACE

Electronic pages

- e11** Elephant in the room

D M Hartung, K Johnston, D M Cohen, T Nguyen, A A Deodhar, D N Bourdette

- e12** Response to: 'Elephant in the room' by Hartung *et al*

R Aggarwal, C V Oddis

- e13** Association between bisphosphonate use and risk of undergoing knee replacement in patients with osteoarthritis

Y Chen, J Zhao, S Lao, W W Lu

- e14** Response to: 'Association between bisphosphonate use and risk of undergoing knee replacement in osteoarthritis patients' by Chen *et al*

T Neogi, S Sheehy, C Peloquin, D Misra, Y Zhang

- e15** Bisphosphonates reduce the risk of knee replacement: we need more analyses!

H-Z Li, X-H Xu, H-D Lu

- e16** Response to: 'Bisphosphonates reduce the risk of knee replacement: we need more analyses!' by Li *et al*

T Neogi, S Li, C Peloquin, D Misra, Y Zhang

- e17** Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?

Y Suyama, M Okada

- e18** Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada

J W Park, J R Curtis, E B Lee